New

Coagulation factor XII, Human, mAb 10-11-37

Monoclonal antibody 10-11-37 recognizes Coagulation Factor XII (FXII, Hageman factor). FXII is a
serine protease and plays a role in blood coagulation, fibrinolysis, kinin and complement systems.
Catalog #: HM2322
Quantity: 100 µg
$474.00

Original supplier of innate immunity products since 1994.

Our commitment to quality: Read more!

Contact our support team for more product information.

Can't find your application for a product? Request a sample!

Description
Details
Monoclonal antibody 10-11-37 recognizes Coagulation Factor XII (FXII, Hageman factor). FXII is a serine protease and plays a role in blood coagulation, fibrinolysis, kinin and complement systems. The protein is the zymogen of the serine protease factor XIIa (FXIIa). FXII is converted to FXIIa through autoactivation induced by contact to charged surfaces, also known as the plasma contact system. FXII is predominantly synthesized in the liver and is composed of fibronectin type I and II domains, two epidermal growth factor-like domains, a kringle region, a proline-rich domain and a catalytic domain. Its molecular weight is approximately 80kDa on SDS-PAGE gel electroforeses. The protein circulates in the plasma at a concentration of 30-35 μg/ml. FXII forms the plasma contact system together with high molecular weight kininogen and plasma kalikrein. FXII autoactivates when these three proteins form a complex on negatively charged nonphysiological surfaces, like inorganic surfaces (eg silicon tubes) or macromolecular organic surfaces (eg heparin) bound to the surface of different cell types, including endothelial cells, platelets and neutrophils. It can trigger blood coagulation and generation of proinflammatory bradykinin. After surface complexation, FXII autoactivates into FXIIa, also called factor XII fragment(XIIf). Once small amounts of kalikrein are formed a positive feedback loop is active leading to enhanced conversion into FXIIa. The activation leads to a series of active enzyme formation. FXIIa converts prekallikrein to kallikrein and kallikrein digests kinogen to liberate proinflammatory bradykinin. Bradykinin triggers inflammatory reactions via activating endothelial cells resulting in vasodilatation, increased vascular permeability and production of other mediators like nitric oxide. The contact system has the ability to activate the complement system via the classical pathway. Simultaneous activation of both systems may lead to pathological conditions, like hereditary angioedema in individuals with dysfunctional C1-inhibitor (C1-IHB). FXIIa can activate complement protein C1r and to a lesser degree C1s in absence of C1-IHB. This leads to unimpeded bradykinin formation resulting in angioedema. Other interactions with complement system are found on the level of gC1qR and MASP-1. The antibody is specific for the heavy chain of FXIIa.
Specifications

Specifications

Catalog number HM2322
Product type Monoclonal antibodies
Quantity 100 µg
Formulation 1 ml (100 μg/ml) 0.2 μm filtered antibody solution in PBS, containing 0.1% bovine serum albumin and
0.02% sodium azide.
Immunogen FXII adsorbed onto Al(OH)3 adjuvant and emulsified in Freund’s Incomplete Adjuvant
Isotype Mouse IgG2a
Species Human
Cross reactivity Mouse - Yes
Alias FXII, Hageman factor
Storage and stability Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.
Precautions For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility
of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is
not responsible for any patent infringements that might result from the use or derivation of this product.
Disease Cardiology and metabolism
Application
Applications
  • Application:
    IA, W
  • Application Notes:
    W: A reduced sample treatment and SDS-Page was used. The band size is 80 kDa (Ref.1) IA: the antibody can be used as coat (Ref.1)
  • Use:
    For Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user’s experimental setting.
References
References
References:
1. Madsen DE, Sidelmann JJ, Overgaard K, Koch C, Gram JB. ELISA for determination of total coagulation factor XII concentration in human plasma J Immunol Methods. 2013, 394:32
Downloads